Dianthus Therapeutics Inc.
$ 47.40
-0.17%
13 Feb - close price
- Market Cap 2,052,232,000 USD
- Current Price $ 47.40
- High / Low $ 49.64 / 47.23
- Stock P/E N/A
- Book Value 12.75
- EPS -3.50
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.29 %
- 52 Week High 57.50
- 52 Week Low 13.37
About
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Analyst Target Price
$73.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-09-18 | 2023-05-11 | 2023-03-07 |
| Reported EPS | -0.97 | -0.88 | -0.82 | -0.81 | -0.72 | -0.51 | -0.54 | -0.71 | -3.78 | -0.8663 | -0.47 | -0.3 |
| Estimated EPS | -0.55 | -0.53 | -0.71 | -0.76 | -0.59 | -0.55 | -0.44 | -1.01 | -0.56 | -3.04 | -0.4 | -0.2762 |
| Surprise | -0.42 | -0.35 | -0.11 | -0.05 | -0.13 | 0.04 | -0.1 | 0.3 | -3.22 | 2.1737 | -0.07 | -0.0238 |
| Surprise Percentage | -76.3636% | -66.0377% | -15.493% | -6.5789% | -22.0339% | 7.2727% | -22.7273% | 29.703% | -575% | 71.5033% | -17.5% | -8.6169% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.97 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNTH
2026-02-12 16:27:46
Dianthus Therapeutics (DNTH) is anticipated to achieve significant clinical milestones in 2026 for CIDP, MMN, and DNTH212, with a strong competitive position based on efficacy and safety. The company holds a robust cash position, expected to extend into 2028, which underpins its substantial commercial potential. This optimistic outlook is based on a Guggenheim Securities Biotech Summit audio transcript.
2026-02-11 16:28:47
Wedbush has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $46.00 to $55.00, maintaining an "outperform" rating, while other analysts also show bullish sentiment with a consensus "Moderate Buy" rating and an average target of $67.63. Despite some insider selling, institutional investors have been modifying their holdings in the company. Dianthus Therapeutics, a clinical-stage biotechnology company, is developing DNTH103 for severe autoimmune and inflammatory diseases.
2026-02-11 09:57:51
Candriam S.C.A. increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 25.3% in the third quarter, acquiring 60,852 shares to hold a total of 301,428 shares valued at $11.86 million. This increase in institutional ownership comes despite significant insider selling, where executives sold 216,538 shares worth approximately $8.28 million. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $66.50.
2026-02-09 08:58:52
Dianthus Therapeutics (DNTH) recently filed a US$600 million universal shelf registration, providing flexibility for future capital raises but also raising concerns about potential shareholder dilution. The clinical-stage biotech is focused on its complement and immunology pipeline, with investors monitoring Phase 2 data and execution risks. Despite a fair value estimate that suggests the stock may be overvalued, the company's participation in a biotech summit aims to enhance visibility.
2026-02-08 12:28:27
Dianthus Therapeutics (DNTH) recently filed a US$600 million universal shelf registration, providing flexibility for future capital access. The stock has seen significant momentum, with a 1-year return of over 120%, and its P/B ratio of 4x is below peers but above the broader US biotech industry, suggesting a nuanced valuation. Investors should consider the potential for dilution and clinical trial outcomes when assessing the company's future.
2026-02-05 12:28:33
Dianthus Therapeutics (NASDAQ: DNTH) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Marino Garcia joining an analyst-led fireside chat and investor meetings on February 12, 2026. The company recently filed an S-3 shelf registration for up to $600 million and holds significant cash reserves of $514-$525 million. Despite this, past stock reactions to similar news have been mixed, suggesting investors are looking for more definitive clinical readouts and financing decisions.
